Ursodeoxycholic acid: Mechanism of action and novel clinical applications

Hepatology Research

Volumn 38, Issue 2, 2008, Pages 123-131

  Ikegami, Tadashi ^a   Matsuzaki, Yasushi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bile acids; Cholestatic liver diseases; Colon cancer; Non alcoholic steatohepatitis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHENODEOXYCHOLIC ACID; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; INSULIN; MIFEPRISTONE; PIROXICAM; PLACEBO; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BILIARY CIRRHOSIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CELL PROTECTION; CHOLELITHIASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL ADENOMA; CYSTIC FIBROSIS; DETOXIFICATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; GALLSTONE DISSOLUTION; HEPATITIS C; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; INTRAHEPATIC CHOLESTASIS; LIPID ABSORPTION; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OBSTRUCTIVE JAUNDICE; OPTIMAL DRUG DOSE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 38049109883     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00297.x     Document Type: Review

References (80)

1. Makino I, Shinozaki K, Yoshino K, Nakagawa S. [Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid]. J Jpn Soc Gastroenterol [Nippon Shokakibyo Gakkai Zasshi] 1975; 72: 690-702. (In Japanese)
2. Salen G, Tint GS, Shefer S. Treatment of cholesterol gallstones with litholytic bile acids. Gastroenterol Clin North Am 1991; 20: 171-82.
3. Corrigan OI, Su CC, Higuchi WI, Hofmann AF. Mesophase formation during cholesterol dissolution in ursodeoxycholate-lecithin solutions: New mechanism for gallstone dissolution in humans. J Pharm Sci 1980; 69: 869-71.
4. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig Dis Sci 1982; 27: 737-61.
5. Festi D, Frabboni R, Bazzoli F et al. Gallbladder motility in cholesterol gallstone disease. Effect of ursodeoxycholic acid administration and gallstone dissolution. Gastroenterology 1990; 99: 1779-85.
6. Portincasa P, van Erpecum KJ, Jansen A, Renooij W, Gadellaa M, vanBerge-Henegouwen GP. Behavior of various cholesterol crystals in bile from patients with gallstones. Hepatology 1996; 23: 738-48.
7. Van Erpecum KJ, Portincasa P, Eckhardt E, Go PM, VanBerge-Henegouwen GP, Groen AK. Ursodeoxycholic acid reduces protein levels and nucleation-promoting activity in human gallbladder bile. Gastroenterology 1996; 110: 1225-37.
8. Tomida S, Abei M, Yamaguchi T et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: A cohort analysis. Hepatology 1999; 30: 6-13.
9. Venneman NG, Besselink MG, Keulemans YC et al. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006; 43: 1276-83.
10. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8: 67-81, vi.
11. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
12. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999; 354: 1053-60.
13. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: Lessons from the past - issues for the future. J Hepatology 2000; 32: 685-8.
14. Trauner M, Boyer JL. Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633-71.
15. Jazrawi RP, de Caestecker JS, Goggin PM etal. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
16. Medina JF, Martinez A, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997; 25: 12-17.
17. Marschall HU, Wagner M, Zollner G et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.
18. Fickert P, Zollner G, Fuchsbichler A et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001; 121: 170-83.
19. Beuers U, Bilzer M, Chittattu A et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 1206-16.
20. Kurz AK, Graf D, Schmitt M, Vom Dahl S, Haussinger D. Tauroursodeoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001; 121: 407-19.
21. Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 2006; 86: 166-74.
22. Kubitz R, Sutfels G, Kuhlkamp T, Kolling R, Haussinger D. Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 2004; 126: 541-53.
23. Kubitz R, Helmer A, Haussinger D. Biliary transport systems: Short-term regulation. Methods Enzymol 2005; 400: 542-57.
24. Roelofsen H, Soroka CJ, Keppler D, Boyer JL. Cyclic AMP stimulates sorting of the canalicular organic anion transporter (Mrp2/cMoat) to the apical domain in hepatocyte couplets. J Cell Sci 1998; 111: 1137-45.
25. Webster CR, Anwer MS. Role of the PI3K/PKB signaling pathway in cAMP-mediated translocation of rat liver Ntcp. Am J Physiol 1999; 277: G1165-72.
26. Bouscarel B, Gettys TW, Fromm H, Dubner H. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: A role for PKC. Am J Physiol 1995; 268: G300-10.
27. Matsuzaki Y, Bouscarel B, Le M et al. Effect of cholestasis on regulation of cAMP synthesis by glucagon and bile acids in isolated hepatocytes. Am J Physiol 1997; 273: G164-74.
28. Ikegami T, Krilov L, Meng J, Patel B, Chapin-Kennedy K, Bouscarel B. Decreased glucagon responsiveness by bile acids: A role for protein kinase C-alpha and glucagon receptor phosphorylation. Endocrinology 2006; 147: 5294-302.
29. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989; 30: 719-30.
30. Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
31. Omata M, Yoshida H, Toyota J et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007; 56: 1747-53.
32. Faubion WA, Guicciardi ME, Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137-45.
33. Reinehr R, Graf D, Haussinger D. Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology 2003; 125: 839-53.
34. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med (Cambridge, Mass) 1998; 4: 165-78.
35. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 1999; 6: 842-54.
36. Webster CR, Anwer MS. Cyclic adenosine monophosphate-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 1998; 27: 1324-31.
37. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1999; 19: 5800-10.
38. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-14.
39. Schoemaker MH, Conde de la Rosa L, Buist-Homan M etal. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004; 39: 1563-73.
40. Sola S, Amaral JD, Castro RE et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 2005; 42: 925-34.
41. Kessel D, Caruso JA, Reiners JJ Jr. Potentiation of photodynamic therapy by ursodeoxycholic acid. Cancer Res 2000; 60: 6985-8.
42. Schlottman K, Wachs FP, Krieg RC, Kullmann F, Scholmerich J, Rogler G. Characterization of bile salt-induced apoptosis in colon cancer cell lines. Cancer Res 2000; 60: 4270-6.
43. Qiao L, Yacoub A, Studer E et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002; 35: 779-89.
44. Ikegami T, Matsuzaki Y, Al Rashid M, Ceryak S, Zhang Y, Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol Cancer Ther 2006; 5: 68-79.
45. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-15.
46. Tanaka H, Makino Y, Miura T et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996; 156: 1601-8.
47. Weitzel C, Stark D, Kullmann F, Scholmerich J, Holstege A, Falk W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 2005; 17: 169-77.
48. Ikegami T, Matsuzaki Y, Fukushima S et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005; 41: 896-905.
49. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83: 319-23.
50. Earnest DL, Holubec H, Wali RK et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994; 54: 5071-4.
51. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: Suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134: 129-39.
52. Martinez JD, Stratagoules ED, LaRue JM et al. Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31: 111-18.
53. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998; 89: 1009-13.
54. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res 1999; 18: 259-66.
55. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977; 39: 2533-9.
56. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995; 36: 268-73.
57. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem 2000; 275: 15090-8.
58. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273: 2424-8.
59. Kurtz WJ, Guldutuna S, Leuschner U. Differing effect of chenodeoxycholic acid and ursodeoxycholic acid on bile acids in rat colonic wall and contents. Tokai J Exp Clin Med 1988; 13: 91-7.
60. Rodrigues CM, Kren BT, Steer CJ, Setchell KD. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995; 109: 1835-44.
61. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998; 58: 1684-7.
62. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 2001; 22: 35-41.
63. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004; 134: 483-6.
64. Im E, Akare S, Powell A, Martinez JD. Ursodeoxycholic acid can suppress deoxycholic acid-induced apoptosis by stimulating Akt/PKB-dependent survival signaling. Nutr Cancer 2005; 51: 110-16.
65. Wali RK, Frawley BP Jr, Hartmann S etal. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: Potential roles of protein kinase C-alpha-beta II, and - zeta. Cancer Res 1995; 55: 5257-64.
66. Roy HK, Bissonnette M, Frawley BP Jr et al. Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. FEBS Lett 1995; 366: 143-5.
67. Serfaty L, De Leusse A, Rosmorduc O et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study. Hepatology 2003; 38: 203-9.
68. Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95.
69. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93.
70. Alberts DS, Martinez ME, Hess LM et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97: 846-53.
71. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: Present and emerging therapies. Semin Liver Dis 2001; 21: 81-8.
72. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 2004; 39: 770-8.
73. Ikemoto S, Takahashi M, Tsunoda N et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 1997; 273: E37-45.
74. Watanabe M, Houten SM, Wang L et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
75. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
76. Zollner G, Fickert P, Fuchsbichler A et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 2003; 39: 480-8.
77. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-7.
78. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42: 1399-405.
79. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23: 1484-90.
80. Jacquemin E, Hermans D, Myara A et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 519-23.